Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascendis Pharma (ASND), Encompass Health (EHC) and L...

Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Encompass Health (EHC)

Ascendis Pharma ( ($ASND) ) has shared an update. Ascendis Pharma A/S reported that on March 30, 2026, the exercise window for its outstanding warr...

Ascendis Pharma Expands Share Capital Following March 30 Warrant Exercises

Ascendis Pharma ( ($ASND) ) has provided an update. On March 23, 2026, Ascendis Pharma held its Annual General Meeting in Denmark, with 90.16% of o...

Ascendis Pharma Shareholders Back Board, Loss Carryforward and New Buyback Mandate at 2026 AGM

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cogent Biosciences (COGT – Research Report) and Asce...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ASND	$232.39	+5.40%	606.93K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ASND	$232.39	+5.4%	606.93K
3
4
5
6

ASND

ASND

Get Ascendis Pharma A/S Data in Excel

Get Ascendis Pharma A/S Data in Excel